Announcements Trials

Browse Landscape

Phase

Phase NA 4 Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 17 Gastrointestinal 13 Thoracic 11 Breast 11 Head & Neck 9 Other hematologic neoplasm 7 CNS 6 Gynecologic 5 Lymphoid 4 Tumor-Agnostic 3 Dermatologic 2 Sarcoma 1 Plasma cell 1 Other solid neoplasm 1 Myeloid 1 Endocrine 1

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Everolimus 27 pembrolizumab 25 Temozolomide 24 lutetium Lu 177 dotatate 22 Nivolumab 18 Magnetic Resonance Spectroscopy 18 lenvatinib 17 cabozantinib 17 Cisplatin 16 Sunitinib 15 Capecitabine 14 Bevacizumab 14 Specimen Handling 12 Sorafenib 12 trametinib 10 Ipilimumab 10 Etoposide 10 pasireotide 9 dabrafenib 9 Paclitaxel 9 Carboplatin 8 pazopanib 7 lanreotide 7 Octreotide 7 Fluorodeoxyglucose F18 7 anlotinib 6 Irinotecan 6 Injections 6 Doxorubicin 6 surufatinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Standard of Care × Endocrine × Clear all

NCT07337447 2026-01-13

REWENEC 01

Hospices Civils de Lyon

Phase 2 Not yet recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡